Trial NCT04860739, EudraCT2021-001978-37
Publication Borobia A M, Lancet, 2021
Primary outcome on the report: Reactogenicity and immunological response to vaccination as per antibodies against SARS-CoV-2 spike protein titres measured by immunoassay 14 days after the BNT162b2 dose.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.